CorMedix Inc (NYSEAMERICAN:CRMD) is a biopharmaceutical company that focuses on the manufacture of therapeutic products. These products play a major role in the treatment and prevention of inflammatory and infectious diseases.
A close outlook
This business guru unveiled the financial results for the second quarter and still went ahead to give an update on the latest business undertakings.
The Chief Executive Officer of CorMedix Khoso Baluch opined, “We were thrilled to have recently announced the best-case scenario outcome for our LOCK-IT-100 interim analysis, with the Data Safety Monitoring Board recommending the trial be halted for efficacy and data submitted to the FDA.”
Baluch went further to outline that the company’s clinical team directed a huge deal of effort towards the locking of the interim data set.
Baluch applauded the remarkable results and wishes the company well as it embarks on completing the latest trial. From that point the company will get in touch with the FDA. The company’s objective is to formulate the next move in line with the Neutrolin development plan. Upon reaching an agreement with the FDA, the business guru will plan on the way forward.
This official believes Neutrolin has all it takes to enhance patient care in a meaningful way. The various costly and potentially deadly catheter-related bloodstream infections make life unbearable for quite a significant number of people. Eliminating these is important and the company says it has the data validating Neutrolin’s efficacy at hand.
Baluch says it is a good thing that they have with them enough capital that will steer them beyond the FDA meeting. Later on, they intend undertake an evaluation of the company’s options and capital needs in a bid to get to the NDA filing.
CorMedix Inc also applauded FDA’s latest move. The body agreed to the company’s request to regain compliance with its continued listing standards. The body gives the company a plan period through December the following year.
In the course of the plan period, the company will try to conform to the set standards to avoid chances of getting delisted.